# NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/NCNA/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: NCNA
Company: NuCana plc
Source: NuCana plc
Published: 2026-05-14 20:01 EST
Original Source URL: https://ir.nucana.com
## Summary

Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, May 14, 2026 (GLOBE

## Article Body
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, May 14, 2026 (GLOBE
## Recent Company News
- 2026-06-01 12:00 EST — [NuCana Appoints Ian Webster as Chief Financial Officer](https://biopharmsignal.com/news/NCNA/nucana-appoints-ian-webster-as-chief-financial-officer) — Source: NuCana plc
- 2026-05-14 20:01 EST — [NuCana Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/NCNA/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: NuCana plc
- 2026-03-19 20:01 EST — [NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/NCNA/nucana-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update) — Source: NuCana plc
- 2026-01-06 13:00 EST — [NuCana Appoints Theresa Bruce as Chief Operating Officer](https://biopharmsignal.com/news/NCNA/nucana-appoints-theresa-bruce-as-chief-operating-officer) — Source: NuCana plc
- 2025-12-10 13:00 EST — [NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma](https://biopharmsignal.com/news/NCNA/nucana-presents-latest-data-demonstrating-clinical-activity-and-favorable-safety-for-nuc-7738-in-patients-with-pd-1-resistant-melanoma) — Source: NuCana plc
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)